Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Vectura Signs Agreement with Aerami Therapeutics | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Vectura Signs Agreement with Aerami Therapeutics

Will support the development of imatinib for the treatment of Pulmonary Arterial Hypertension

By: Contract Pharma

Contract Pharma Staff

Vectura Group plc, an inhalation CDMO, has signed of a global license and development agreement with Aerami Therapeutics Inc. for inhaled imatinib (VR325) for the treatment of Pulmonary Arterial Hypertension.
 
Aerami will be responsible for the overall development and commercialization of inhaled imatinib, with Vectura providing development services expertise and a license to its Fox mesh nebuliser technology.
 
Under the partnership, Vectura will receive development fees, revenue from the provision of Fox nebulizer devices and mid-single digit royalties from global net sales of imatinib, together with regulatory and success-related milestone payments.  There is no upfront payment.
 
“Pulmonary Arterial Hypertension is a rare, progressive, fatal disease with approximately 500-1000 new cases diagnosed each year in the U.S. alone according to the National Organization for Rare Disorders1. In working together with Aerami, this programme has the potential to impact the lives of patients around the world,” commented Will Downie, CEO of Vectura. “Our deep inhalation expertise, especially now as a CDMO, perfectly complements the scientific capability of Aerami in the biotechnology field. We look forward to developing a strong partnership for years to come.”
 
VR325, inhaled imatinib, was first developed by Vectura as part of its former specialty pharma pipeline. As the company pivoted to a strategy focused on the CDMO market, it announced it would cease further investment in this portfolio, instead providing development services to a more diverse range of biotech and pharmaceutical companies in the growing inhalation CDMO space.
  
Reference
1 rarediseases.org/rare-diseases/pulmonary-arterial-hypertension/

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics